JP2020506243A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020506243A5 JP2020506243A5 JP2019563650A JP2019563650A JP2020506243A5 JP 2020506243 A5 JP2020506243 A5 JP 2020506243A5 JP 2019563650 A JP2019563650 A JP 2019563650A JP 2019563650 A JP2019563650 A JP 2019563650A JP 2020506243 A5 JP2020506243 A5 JP 2020506243A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- influenza
- composition according
- virus
- naphthamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000712461 unidentified influenza virus Species 0.000 claims description 22
- 150000003839 salts Chemical class 0.000 claims description 16
- 241000712431 Influenza A virus Species 0.000 claims description 8
- 230000009385 viral infection Effects 0.000 claims description 8
- 241000197306 H1N1 subtype Species 0.000 claims description 4
- 241000252870 H3N2 subtype Species 0.000 claims description 4
- 241001473385 H5N1 subtype Species 0.000 claims description 4
- 241000713196 Influenza B virus Species 0.000 claims description 4
- 230000010076 replication Effects 0.000 claims description 4
- 208000024891 symptom Diseases 0.000 claims description 4
- 239000003443 antiviral agent Substances 0.000 claims description 3
- WVROWPPEIMRGAB-UHFFFAOYSA-N bit225 Chemical compound C1=NN(C)C=C1C1=CC=CC2=CC(C(=O)NC(N)=N)=CC=C12 WVROWPPEIMRGAB-UHFFFAOYSA-N 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 206010022000 influenza Diseases 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 241000713297 Influenza C virus Species 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 229960003752 oseltamivir Drugs 0.000 claims description 2
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 claims description 2
- XRQDFNLINLXZLB-CKIKVBCHSA-N peramivir Chemical compound CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@@H](C(O)=O)C[C@H]1NC(N)=N XRQDFNLINLXZLB-CKIKVBCHSA-N 0.000 claims description 2
- 229960001084 peramivir Drugs 0.000 claims description 2
- 229960001028 zanamivir Drugs 0.000 claims description 2
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 17
- 102000004310 Ion Channels Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2017900385A AU2017900385A0 (en) | 2017-02-08 | Methods of treating influenza | |
| AU2017900385 | 2017-02-08 | ||
| PCT/AU2018/050085 WO2018145148A1 (en) | 2017-02-08 | 2018-02-07 | Methods of treating influenza |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020506243A JP2020506243A (ja) | 2020-02-27 |
| JP2020506243A5 true JP2020506243A5 (OSRAM) | 2021-03-11 |
| JP7019727B2 JP7019727B2 (ja) | 2022-02-15 |
Family
ID=63106827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019563650A Active JP7019727B2 (ja) | 2017-02-08 | 2018-02-07 | インフルエンザの治療方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10918623B2 (OSRAM) |
| EP (1) | EP3579833B1 (OSRAM) |
| JP (1) | JP7019727B2 (OSRAM) |
| KR (1) | KR102607599B1 (OSRAM) |
| CN (1) | CN110325187B (OSRAM) |
| AU (1) | AU2018218179B2 (OSRAM) |
| BR (1) | BR112019016316A2 (OSRAM) |
| CA (1) | CA3052503A1 (OSRAM) |
| ES (1) | ES2910136T3 (OSRAM) |
| MX (1) | MX387115B (OSRAM) |
| RU (1) | RU2769317C2 (OSRAM) |
| SG (1) | SG11201907034PA (OSRAM) |
| WO (1) | WO2018145148A1 (OSRAM) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20130400A1 (es) | 2010-07-22 | 2013-04-10 | Gilead Sciences Inc | Metodos y compuestos para tratar infecciones virales por paramyxoviridae |
| TWI698444B (zh) | 2014-10-29 | 2020-07-11 | 美商基利科學股份有限公司 | 製備核糖苷的方法 |
| PT3349758T (pt) | 2015-09-16 | 2022-07-13 | Gilead Sciences Inc | Métodos para o tratamento de infeções pelo vírus arenaviridae |
| CN110869028B (zh) | 2017-03-14 | 2023-01-20 | 吉利德科学公司 | 治疗猫冠状病毒感染的方法 |
| KR20190141747A (ko) | 2017-05-01 | 2019-12-24 | 길리애드 사이언시즈, 인코포레이티드 | (S)-2-에틸부틸 2-(((S)-(((2R,3S,4R,5R)-5-(4-아미노피롤로[2,1-f] [1,2,4]트리아진-7-일)-5-시아노-3,4-디히드록시테트라히드로푸란-2-일)메톡시)(페녹시) 포스포릴)아미노)프로파노에이트의 결정질 형태 |
| US10675296B2 (en) | 2017-07-11 | 2020-06-09 | Gilead Sciences, Inc. | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections |
| CN118766947A (zh) | 2020-01-27 | 2024-10-15 | 吉利德科学公司 | 用于治疗SARS CoV-2感染的方法 |
| CA3169340A1 (en) | 2020-03-12 | 2021-09-16 | Pavel R. Badalov | Methods of preparing 1'-cyano nucleosides |
| JP7482250B2 (ja) | 2020-04-06 | 2024-05-13 | ギリアード サイエンシーズ， インコーポレイテッド | １’－シアノ置換カルバヌクレオシド類似体の吸入製剤 |
| PL4157272T3 (pl) | 2020-05-29 | 2025-10-20 | Gilead Sciences, Inc. | Remdesiwir do leczenia zakażeń wirusowych |
| JP2023531524A (ja) | 2020-06-24 | 2023-07-24 | ギリアード サイエンシーズ， インコーポレイテッド | １’－シアノヌクレオシド類似体及びその使用 |
| CR20230100A (es) | 2020-08-24 | 2023-04-28 | Gilead Sciences Inc | Compuestos fosfolípidos y usos de los mismos |
| LT4204421T (lt) | 2020-08-27 | 2024-06-25 | Gilead Sciences, Inc. | Virusinių infekcijų gydymui skirti junginiai ir būdai |
| TW202344257A (zh) | 2020-10-16 | 2023-11-16 | 美商基利科學股份有限公司 | 磷脂化合物及其用途 |
| EP4346772A1 (en) | 2021-05-26 | 2024-04-10 | Gilead Sciences, Inc. | Phospholipid formulations of 1'-cyano substituted carba-nucleoside analogs |
| AU2022328698B2 (en) | 2021-08-18 | 2025-02-20 | Gilead Sciences, Inc. | Phospholipid compounds and methods of making and using the same |
| KR20240110039A (ko) * | 2021-11-24 | 2024-07-12 | 바이오트론 리미티드 | SARS-CoV-2 감염을 치료하는 방법 |
| AU2023227470A1 (en) | 2022-03-02 | 2024-08-29 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
| US20230295172A1 (en) | 2022-03-02 | 2023-09-21 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
| AU2023227862A1 (en) | 2022-03-03 | 2024-09-26 | Gilead Sciences, Inc. | Antiviral compounds and methods of making and using the same |
| PE20250419A1 (es) | 2022-03-03 | 2025-02-14 | Gilead Sciences Inc | Compuestos antivirales y metodos de elaboracion y uso de los mismos |
| KR20250020476A (ko) | 2022-06-06 | 2025-02-11 | 길리애드 사이언시즈, 인코포레이티드 | Sars-cov-2를 포함한 바이러스성 감염을 치료하는 방법 |
| US20240051962A1 (en) | 2022-06-29 | 2024-02-15 | Gilead Sciences, Inc. | Solid forms of a nucleoside analogue and uses thereof |
| US20240043466A1 (en) | 2022-06-30 | 2024-02-08 | Gilead Sciences, Inc. | Solid forms of a nucleoside analogue and uses thereof |
| EP4665737A1 (en) | 2023-02-16 | 2025-12-24 | Gilead Sciences, Inc. | Phospholipid compounds and methods of making and using the same |
| US20250084088A1 (en) | 2023-08-31 | 2025-03-13 | Gilead Sciences, Inc. | Antiviral compounds and methods of making and using the same |
| US20250090537A1 (en) | 2023-08-31 | 2025-03-20 | Gilead Sciences, Inc. | Antiviral compounds and methods of making and using the same |
| US20250099476A1 (en) | 2023-09-06 | 2025-03-27 | Gilead Sciences, Inc. | Solid forms of a nucleoside analogue and uses thereof |
| TW202517647A (zh) | 2023-09-28 | 2025-05-01 | 美商基利科學股份有限公司 | 用於治療病毒感染的化合物及方法 |
| US12357577B1 (en) | 2024-02-02 | 2025-07-15 | Gilead Sciences, Inc. | Pharmaceutical formulations and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ596107A (en) * | 2005-06-24 | 2013-09-27 | Biotron Ltd | Antiviral compounds and methods |
| EP2194976B1 (en) * | 2007-08-03 | 2015-12-09 | Biotron Limited | Hepatitis C antiviral compositions comprising 5-(1-methylpyrazol-4-yl)2-naphthoylguanidine and 2'-C-methyladenosine or 2'-C-methylcytidine |
| KR101369584B1 (ko) * | 2011-04-19 | 2014-03-06 | 일양약품주식회사 | 페닐-이속사졸 유도체 및 그의 제조방법 |
| WO2016007538A1 (en) * | 2014-07-07 | 2016-01-14 | Prophylaxis, Llc | Viral prophylaxis treatment methods and pre-exposure prophylaxis kits |
| CN110870864B (zh) | 2018-08-29 | 2021-09-24 | 复旦大学 | 马来酸卡比沙明在制备抗流感病毒药物中的应用 |
-
2018
- 2018-02-07 BR BR112019016316-6A patent/BR112019016316A2/pt not_active Application Discontinuation
- 2018-02-07 KR KR1020197024919A patent/KR102607599B1/ko active Active
- 2018-02-07 CA CA3052503A patent/CA3052503A1/en active Pending
- 2018-02-07 CN CN201880010492.9A patent/CN110325187B/zh active Active
- 2018-02-07 ES ES18751710T patent/ES2910136T3/es active Active
- 2018-02-07 SG SG11201907034PA patent/SG11201907034PA/en unknown
- 2018-02-07 RU RU2019126746A patent/RU2769317C2/ru active
- 2018-02-07 WO PCT/AU2018/050085 patent/WO2018145148A1/en not_active Ceased
- 2018-02-07 AU AU2018218179A patent/AU2018218179B2/en active Active
- 2018-02-07 EP EP18751710.7A patent/EP3579833B1/en active Active
- 2018-02-07 MX MX2019009443A patent/MX387115B/es unknown
- 2018-02-07 JP JP2019563650A patent/JP7019727B2/ja active Active
- 2018-02-07 US US16/483,958 patent/US10918623B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020506243A5 (OSRAM) | ||
| RU2019126746A (ru) | Способы лечения гриппа | |
| Liao et al. | Germacrone inhibits early stages of influenza virus infection | |
| Hayden | Antivirals for influenza: historical perspectives and lessons learned | |
| IL321503A (en) | Recombinant virus, composition comprising the same, and uses thereof | |
| Yen | Current and novel antiviral strategies for influenza infection | |
| Tarbet et al. | Combinations of favipiravir and peramivir for the treatment of pandemic influenza A/California/04/2009 (H1N1) virus infections in mice | |
| IN2012DN01254A (OSRAM) | ||
| Haasbach et al. | The NF-kappaB inhibitor SC75741 protects mice against highly pathogenic avian influenza A virus | |
| Liu et al. | A small-molecule compound has anti-influenza A virus activity by acting as a ‘‘PB2 inhibitor” | |
| HRP20130163T1 (hr) | Ljudske molekule za vezanje koje mogu neutralizirati virus influence h5n1 i njihova uporaba | |
| JP2014510130A5 (OSRAM) | ||
| Meseko et al. | Antiviral options and therapeutics against influenza: history, latest developments and future prospects | |
| Govorkova et al. | Therapeutics against influenza | |
| Kumar et al. | Oseltamivir analogs with potent anti-influenza virus activity | |
| Kiselev et al. | A new antiviral drug Triazavirin: results of phase II clinical trial | |
| US20140121237A1 (en) | Methods for Inhibiting Virus Replication | |
| Yang et al. | Influenza virus entry inhibitors | |
| Liu et al. | Repurposing anticancer drugs targeting the MAPK/ERK signaling pathway for the treatment of respiratory virus infections | |
| Li et al. | Cilnidipine exerts antiviral effects in vitro and in vivo by inhibiting the internalization and fusion of influenza A virus | |
| Leyva-Grado et al. | Aerosol administration increases the efficacy of oseltamivir for the treatment of mice infected with influenza viruses | |
| WO2017201030A1 (en) | Methods of treating viral infection | |
| Park et al. | Antiviral agents against influenza viruses | |
| NZ755900B2 (en) | Methods of treating influenza | |
| Bavagnoli et al. | The 2009 influenza pandemic: promising lessons for antiviral therapy for future outbreaks |